Protocol Single compound

Sermorelin

GHRH(1-29)

GHRH(1-29) amide referenced in growth-hormone-releasing-hormone receptor research.

Laboratory reference · in vitro research data

Research vial sizes: 5 mg · 10 mg
Dosing data: Not listed — reference entry covers vial concentration only.
Storage: Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.

Concentration per BAC-water volume; 10 units = 0.1 mL on a U-100 syringe.

Vial	BAC water	mg/mL	mg per 10 u
5 mg	1 mL	5	0.5
5 mg	2 mL	2.5	0.25
5 mg	3 mL	1.67	0.167
10 mg	1 mL	10	1
10 mg	2 mL	5	0.5
10 mg	3 mL	3.33	0.333

Draw to

—units

= — mL on a U-100 syringe

Syringe

U-100 · 100 units (1 mL)2 unit per line

Sermorelin is the first 29 amino acids of GHRH, the shortest fully active fragment. It stimulates pituitary GHRH receptors to release GH.

Used intravenously as a diagnostic test for GH deficiency, though a normal response cannot rule out hypothalamic causes.
In some prepubertal children with idiopathic GH deficiency, height velocity increased significantly over 12 months, with limited data to 36 months.

Was FDA-approved (Geref) but the branded product was discontinued; it is now mainly compounded or sold for research.
Listed as prohibited in sport by the World Anti-Doping Agency.

Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139–157.1999-08Drug reviewRead paper ↗
Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307–308.2006EditorialRead paper ↗

Listings are provided for reference — always verify the latest third-party COA before purchasing.

See site

Featured supplier · third-party tested, COA published per batch

TBD

Placeholder — details coming soon

View productView COA

TBD

Placeholder — details coming soon

View productView COA